Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference
December 04 2017 - 8:00AM
Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed
to the development and commercialization of innovative products in
women’s reproductive health, today announced that Sabrina Martucci
Johnson, President and Chief Executive Officer, will present at the
LD Micro 10th Annual Main Event Conference on Wednesday, December
6, 2017 at 3:00 p.m. Pacific Time in Los Angeles, CA. Ms. Johnson
will provide a Daré overview and business update.
The presentation will be webcast live and may be accessed by
visiting Daré’s website at http://ir.darebioscience.com. A replay
of the webcast will be available for 10 business days.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company
committed to the advancement of innovative products for women's
reproductive health. Daré is driven by a mission to identify,
develop and bring to market a diverse portfolio of novel therapies
that expand treatment options, improve outcomes and facilitate
convenience for women. The Company is initially focused on the
areas of contraception, vaginal health and fertility. Daré's first
product candidate, Ovaprene™, is a monthly non-hormonal
contraceptive ring that is currently in clinical studies. Daré's
executive management team brings experience in global women's
healthcare as well as a track record of success in prior ventures
in financing, partnering, commercializing, and achieving regulatory
approval for medical devices, therapeutics and diagnostics. For
more information on Daré, please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of The Private Securities Litigation Reform Act of 1995
regarding matters that are not historical facts, including
statements relating to Daré's expectations regarding the
anticipated market demands for its products, the safety and
effectiveness of its products, market acceptance of Daré's products
and the qualifications and expertise of Daré's management team.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements as a result of various
important factors, including the uncertainties inherent in the
initiation and completion of clinical trials; availability and
timing of data from ongoing and future clinical trials and the
results of such trials; whether preliminary results from a clinical
trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory
approvals; claims of infringement and other risks relating to
Daré's owned and licensed intellectual property rights, and other
factors discussed in the "Risk Factors" section of Daré's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on November 13 , 2017. Additional information concerning
factors that could cause actual results to materially differ from
those in the forward-looking statements is contained in Daré's
reports to the Securities and Exchange Commission, including Daré's
reports on Forms 10-Q, 8-K and 10-K. In addition, any
forward-looking statements included in this press release represent
our views only as of the date of this release and should not be
relied upon as representing our views as of any subsequent date.
Daré specifically disclaims any obligation to update any
forward-looking statements included in this press release.
CONTACT:innovations@darebioscience.comPhone:
858-926-7655
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Apr 2024 to May 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From May 2023 to May 2024